Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 5
The 1985 outbreak of bovine spongiform encephalopathy, or mad cow disease, in the United Kingdom generated global awareness of a previously obscure set of neurodegenerative diseases called transmis- sible spongiform encephalopathies (TSEs). TSEs are caused by infectious agents. Yet, unlike all other known infectious diseases, TSE infectivity ap- pears to be associated with an abnormally folded protein known as a prion (Prusiner, 19821. There is no cure, prophylaxis, or fail-safe antemortem diagnostic test for TSEs, often called prion diseases. Infected hosts incubate a TSE for months to decades, and their health declines rapidly after the onset of clinical symptoms; death invariably follows within a period of months. Bovine spongiform encephalopathy (BSE) became an epidemic that af- fected hundreds of thousands of animals in the United Kingdom and in- flicted economic harm on the country's cattle and beef industries. Cases of BSE have also been reported in continental Europe, Israel, Japan, Canada, and elsewhere.) Exposure to BSE-infected beef products has given rise to a fatal human neurodegenerative disease called variant Creutzfel~t-Takob dis- ease (vCJD), first identified in 1996 (Will et al., 19961. As of September 2, 2003,140 definite or probable vCTD cases had been identified in the United Kingdom (National Creutzfel~t-Takob Disease Surveillance Unit, 2003), and a handful of cases had been identified in other countries. Estimates of the total number of people who will contract vCJD as a result of the BSE epi- iEDITORS' NOTE: After this report was completed, the first U.S. case of BSE was identi- fied in Washington State and was announced to the public on December 23, 2003.
OCR for page 6
6 ADVANCING PRION SCIENCE demic vary depending on assumptions regarding the incubation period, in- dividual susceptibility, and the level of exposure. The incubation period for another human prion disease, kuru, is 4 to 40 years (Huillard d'Aignaux et al., 20021. The origin of vCJD in prior-infected cattle raises the concern that chronic wasting disease (CWD), a prion disease spreading among North American deer and elk (Williams and Miller, 2002), could cause disease in people who consume venison from the affected regions. The European Commission has spent millions of euros on research to develop better diagnostics for TSEs, especially BSE, with modest success. Commercial diagnostic tests have been developed for rapid postmortem BSE detection and are used throughout the United Kingdom and Europe. These tests cannot detect prions present at low levels, however. The lack of highly sensitive, accurate, and rapid tests has led to such controls as cat- egorical importation bans and massive culling of herds to ensure the safety of beef products. To date the U.S. Food and Drug Administration (FDA) has received no request to approve a rapid test for the detection of human TSEs (personal communication, D.M. Asher, FDA, July 1, 20031. However, the U.S. De- partment of Agriculture's (USDA) Center for Veterinary Biologics has ap- proved the use of three rapid tests for the detection of CWD in cervids (personal communication, R. Hill, USDA APHIS Center for Veterinary Biologics, November 25, 20031. ORIGINS OF THIS STUDY The economic and health consequences of BSE and vCJD in Europe and the risk that U.S. military forces stationed abroad and their dependents could contract a TSE through infected beef or contaminated blood products led the U.S. Congress to pass a law establishing the National Prion Re- search Project (NPRP) in 2002 (U.S. Senate Committee on Appropriations, 20011. NPRP funds research on TSEs, with special emphasis on developing . . an antemortem ~ Agnostic test. Congress mandated that the U.S. Department of Defense (DOD) ad- minister the new project, which was delegated to the Army's Medical Re- search and Materiel Command (MRMC). MRMC administers grants through a two-tiered process of external scientific peer review, followed by programmatic review by a multidisciplinary group of DOD and civilian experts called an integration panel. MRMC requested that the Institute of Medicine (IOM) produce two reports assessing present scientific knowI- edge about TSEs and recommending the highest-priority research for fund- ing (Department of Army Contract DAMD17-02-C-0094, May 20021.
OCR for page 7
SUMMAR Y 7 In Tune 2002, IOM formed the Committee on Transmissible Spongiform Encephalopathies: Assessment of Relevant Science to conduct this study. The committee was charged with evaluating the state of prion science, especially as regards research needs in the area of diagnostics. The members of the committee were asked to examine novel technologies that might advance diagnostics; evaluate the reagents and assays used in prion research and recommend improvements; evaluate the adequacy of the TSE research infrastructure in the United States with respect to the number of investigators, physical facilities, and training needs; suggest opportunities for collaboration with foreign investigators; evaluate the threat of TSEs to U.S. military forces with respect to their food supply, their blood supply, and any other factors; provide advice on public health policies or surveil- lance programs that require new research or that might affect the military; and recommend additional research on ways to reduce or prevent TSEs. The committee's first report, released in January 2003, advised MRMC's integration pane! on the most promising avenues of research for developing antemortem TSE diagnostic tests. It also recommended ways to remedy key shortcomings in the U.S. infrastructure for TSE research and evaluated the degree of risk posed by TSEs to U.S. military forces and their dependents stationed abroad. This, the committee's second report, recom- mends the highest-priority research in TSE surveillance, prevention, and therapy. It includes an updated version of the material from the first report, with an additional chapter on the unique challenges of detecting TSE infec- tivity in blood. This summary presents the committee's conclusions and recommendations, which are also listed in Table S-1. Clearly, we believe all the recommendations in this report are impor- tant. Given that NPRP has a limited amount of resources, however, it can act only on a limited number of recommendations each fiscal year. There- fore, we prioritized our recommendations by placing them in one of three ranks, 1 being the highest (see Table S-11. We assigned approximately a third of the recommendations to each rank. The rankings are based on the following criteria: · Impact on public health · Impact on protecting animal health (mainly cattle) · Impact on protecting the U.S. economy (BSE/CWD) · Impact on advancing scientific understanding of prions (potential for breakthroughs) · The need to accomplish first rather than second (stepwise progres- sion of the science) · Return on investment · Likelihood of success (How feasible is it?)
OCR for page 8
8 ADVANCING PRION SCIENCE In addition to prioritizing all of our recommendations, we indicate in the body of the report the most urgent and critical areas of research related to recommendations 3.1 and 6.4. PRIONS AND PrPSC: DEFINITIONS AND USAGE This report uses the terms prion and PrPSc interchangeably in reference to the pro/ease-resistant protein associated with prion disease.2 The com- mittee is sensitive to the fact that such usage is controversial, however, so we want to explain our choice of words in the context of this controversy. The proteins PrPSc and prpC are both encoded by the PRNP gene on chromosome 20 in humans. Like all proteins, prpC has a characteristic con- formation. Under certain conditions, however, it folds into an abnormal shape that is associated with fatal neurodegeneration after a long incuba- tion period. This misfolded protein is called PrPSc. The committee believes that the preponderance of scientific evidence favors the hypothesis that priors, consisting of PrPSc, are associated with infection in TSEs. If prion aggregates are the infectious agent that causes TSEs and if a prion is the misfolded protein known as PrPSc, then by parallel reasoning, aggregates of PrPSc are the infectious agent of TSEs. However, some reputable TSE experts believe that PrPSc alone may not be sufficient to cause a TSE infection, although the protein may be associ- ated with and even necessary for such infection. A number of these investi- gators hypothesize that the infectious particle the prion may contain hid- den nucleic acid, additional proteins, or some other additional, essential material. This camp uses the term prion to refer to TSE infectivity, but does not equate prion with PrPSc. To respect and recognize this point of view, this report often uses the phrase "the infectious agent of ELSE under discus- sion]" instead of the term prion or PrPSc. The purpose of this report is not to resolve the controversy over the definition of a prion or to proffer the committee's opinion regarding the hypothesis that prions consist exclusively of the protein PrPSc. Rather, the purpose of this report is to call for additional research especially studies of the fundamental molecular structures and mechanisms related to TSEs- so that disparate views may converge and advance prion science. 2At times an additional term, PrPreS, is used synonymously with PrPSc. PrPreS is an abnor- mally folded prion protein that is highly resistant to digestion by the enzyme proteinase K (PK) and is strongly associated with prion disease. Unlike PrPreS, however, PrPSc demonstrates a gradient of resistance to PK. PrPSc is associated with infectious potential and with prion disease even in circumstances where it may be sensitive to PK digestion.
OCR for page 9
SUMMAR Y 9 BASIC BIOMEDICAL RESEARCH The committee determined that the main obstacle to developing sensi- tive, specific antemortem diagnostics for TSEs is the lack of knowledge about prions and their normal cellular isoform, PrPC. Recommendation 3.1:3 Fund basic research to elucidate (1) the structural features of priors, (2) the molecular mechanisms of prion replication, (3) the mechanisms of pathogenesis of transmissible spongiform encephalopathies, and (4) the physiological function of prpc. The committee believes basic research in these four areas will supply the knowledge required to advance TSE diagnostics more quickly than ap- plied research alone. The report text describes specific gaps in knowledge that need to be filled in each of the four areas. For instance, present models of prion conformation and tertiary struc- ture are neither complete nor conclusive. Defining the structural differences between PrP isoforms could enable scientists to synthesize a PrPSc-specific antibody probe or aptamer. Defining the structures of prpC and PrPSc at the sites where they interact during binding and conformational change could support the development of molecules that would block those interactions. Most experts believe the conversion of prpC to PrPSc and the accumula- tion of prions require the assistance of one or more molecules (Caughey, 2001) that may be easier to detect than prions themselves. These unidenti- fied ancillary or chaperoning factors could serve as surrogate markers for prion detection and as drug targets for TSE therapeutics and prophylaxes. Current gaps in knowledge of the pathogenesis of prion diseases pre- vent better characterization of diagnostic targets and strategies. The routes of transmission, the factors that influence host susceptibility, the lack of an immune response, the mechanisms of neuroinvasion, and the cause or causes of cellular toxicity all lack satisfactory explanations; filling these gaps would result in tests with greater sensitivity and specificity. In addition, isolating the multiprotein complexes that contain prions might make it possible to identify new cofactors important to the formation and stabilization of PrPSc and infectivity. Understanding the normal role of prpC might also reveal associated molecules and pathways that would be appropriate detection targets for TSE diagnostics. Investigators should clarify whether the basis for nerve cell dysfunction and death in prion disease is related to the toxicity of PrPSc, to 3For ease of reference, the committee's recommendations are numbered according to the chapter of the report in which they appear. For instance, recommendation 3.1 is the first recommendation in Chapter 3.
OCR for page 10
10 ADVaNCING PRION SCIENCE the loss of function of prpC as a result of its conversion to PrPSC and its aggregation during a prion infection, or to other factors. Finally, the committee concluded that too great a focus on applied rather than basic research would slow progress in TSE diagnostics. TSE DL\GNOSllCS Obstacles to Developing Antemortem Diagnostics for TSEs Conventional methods used to diagnose most infectious diseases, such as malaria, tuberculosis, hepatitis, and AIDS, fail to detect prion diseases for numerous reasons. First, a prion is a host protein with an altered con- formation such that the immune system does not recognize it as foreign and does not produce antibodies against it. Second, since a prion lacks DNA and RNA, it cannot be identified by molecular methods such as polymerase chain reaction and other nucleic acid-based tests, nor can it be identified by such customary methods as direct visualization under a light microscope, cultivation in the laboratory, or detection of specific antibodies or antigens by standard immunological methods. Moreover, prions are largely in- soluble, distributed unevenly in body tissues, and found in a limited set of tissues by currently available tests. PrPSc is neurotropic, so it ultimately affects cells of nervous system tissues. Yet where and how PrPSc progresses through the body before its final assault on the nervous system are largely unclear, complicating the ability to locate and detect it. In addition, the similarities between prions and the normal host cellular protein prpC pose a fundamental problem. Since it is normal to find prpC in healthy individuals, detection tests must differentiate between the normal and abnormal prion protein molecules. The most common strategy thus far has been to mix the test material with the proteinase K enzyme (PK), which digests normal prion protein but only a portion of the abnormally folded protein. Various techniques are then used to detect the residual PrPSc after digestion. This process incidentally reduces the small amount of original PrPSc captured, however, making the process less sensitive than the newer experimental methods that do not rely on PK digestion. The fact that only small amounts of abnormal prion protein may be available for detection in accessible living tissues such as blood, urine, and cerebrospinal fluid challenges diagnosticians to develop a sufficiently sensi- tive test. Such a test must differentiate not only between normal and abnor- mal prion proteins, but also, for some purposes, between one or more strains of PrPSc a challenge resulting from basic deficiencies in the understanding of prion strain diversity and the nature of strain variation. The ultimate objective of a prion detection test is to detect a single infectious unit while avoiding a false-positive test result.
OCR for page 11
SUMMAR Y 11 Presently Available TSE Diagnostics The diagnostic assays available today are generally used only after the death of an animal or person. These assays test brain tissue, where the greatest concentrations of prions are found during the terminal stage of disease. Standard histopathological and immunohistochemical techniques are used to view the tissue microscopically and identify characteristic vacu- oles, plaques, or other abnormal features and staining associated with prion diseases. The standard confirmatory test is the Western blot. Attempts made to date to develop accurate, rapid, and highly sensitive antemortem tests, especially for detecting prions early in the course of infec- tion, have largely failed. Also, most tests still involve PK digestion, and the specificity and sensitivity of tests that do not use PK require further demon- stration. Newer tests appear to have improved the limits of detection. As of this writing, however, most of the newer detection methods are experimen- tal and have not been independently verified and reported. Moreover, the sensitivity of these tests must still be improved by several orders of magni- tude if they are to reliably detect an infectious unit of priors. Recommendation 4.1: Fund research to clevelop new assays most likely to achieve quantum leaps in the quality of prion detection tools, rather than incremental improvements to existing tests. Any efforts to improve existing tests shouic! aim to increase their sensi- tivities by several orclers of magnitude (at least 103~. The optimal test shouic! detect less than 1 infectious unit (IU) of PrPSc per unit of ultimate product used (e.g., 1 liter of blooc! or 100 grams of beefl. Recommendation 4.2: Fund research to improve in vitro tech- niques that amplify small amounts of PrPSc to enhance the sensitivi- · ~ · ~ ties ot c Agnostic tests. The Need for Novel Approaches to Developing TSE Diagnostics Major improvements in TSE diagnostics must await the availability of novel testing techniques or of reagents designed to specifically target PrPSc. Recommendation 4.3: Fund research to clevelop novel methods and reagents that detect or bind to priors, inclucling new antibodies, pepticles, nucleic acids, synthetic derivatives, and chimeric mol- ecules. This research couic! leac! not only to better diagnostics, but also to better therapeutic and prophylactic strategies. Researchers have attempted a variety of novel ways to improve the sensitivities of tests for TSEs. The most promising of these techniques are summarized below.
OCR for page 12
12 Surrogate Markers ADVANCING PRION SCIENCE A strategy other than the direct detection of PrPSc is to detect surrogate markers of prion infection. Cells that have been injured by prion invasion may produce other unique proteins or protein mixes that can be detected. The committee determined that the rapidly expanding field of proteomics may offer new tools for the development of highly sensitive prion detection tests employing such surrogate markers. This strategy is being used success- fully for the detection of certain cancers (Petricoin et al., 2002a,b), and the committee recommends that it be applied to TSEs. Recommendation 4.4: Fund research to identify surrogate markers or signatures for the detection of prions or prion diseases. Prion Amplification As indicated in recommendation 4.2, the committee also sees promise in strategies for amplification of PrPSc material before further testing (Saborio et al., 20011. Analogous to the polymerase chain reaction tech- nique for amplifying small amounts of DNA, these strategies could signifi- cantly boost the power of prion diagnostics. Cell Culture Assays In vitro culture systems have been used for prion detection with moder- ate success. Yet the committee believes these assays would hold great prom- ise if a stable and robust cell culture assay were developed. Their speed and biological simplicity would make them highly effective in testing for TSEs. Recommendation 4.5: Fund research to improve techniques for propagating prions in cultured cells and develop new in vitro cell systems as a means to assay and study priors. Clinical Diagnostics Although clinical criteria for the characterization of prion diseases have been established, they are adjunctive at present. Neuroimaging offers prom- ise as a future clinical diagnostic too! for prion diseases. The committee concluded that newer magnetic resonance imaging techniques, positron emission tomography scanning applications, and multiphoton microscopy should be developed for antemortem detection of TSEs. Recommendation 4.6: Fund research to develop functional imag- ing for the presence of PrPSc in brain tissue, leading to an early
OCR for page 13
SUMMAR Y diagnostic test similar to the imaging diagnostics being developed for Alzbeimer's disease. TESTING BLOOD FOR EVIDENCE OF TSEs 13 The ability to detect prions in blood would enable diagnosis and treat- ment of a TSE at an early stage of the disease, ideally before neuroinvasion. It would also allow a TSE-infected donor to be identified and deferred be- fore his or her blood is taken and administered to others as whole blood, a blood product, or a blood derivative. In addition, a test for TSE infectivity in blood could allow donors currently deferred because of potential expo- sure to a TSE agent to reenter the donor pool. In animals, such a test would permit early recognition of infection and timely control procedures. The committee believes the development of a screening test for detecting prions in blood is desirable for all these reasons, but will be extremely challenging to accomplish. The findings of TSE transmission studies in animals give reason to be- lieve that prions can be found in blood (Brown, 20011. Most of those stud- ies used the most sensitive form of in viva assay, an injection of blood directly into the brain, to see whether the animals would become infected; some did. In addition, a limited number of studies showed that blood from infected animals could infect by the intravenous route. Those studies more closely simulate exposure by blood transfusion. Recent compelling studies in sheep demonstrated that both the BSE and scrapie agents could be trans- mitted to other sheep by blood transfusion (Hunter et al., 2002), support- ing the hypothesis that blood can serve as reservoir for infectious priors. Multiple transmission and case-control studies have failed to demon- strate that blood from patients with sporadic Creutzfel~t-Takob disease (sCTD) is infectious (Brown et al., 19941. By contrast, investigations into the transmissibility of the vCTD agent through blood transfusion are just beginning to gain momentum. Because a significant amount of prions ap- pears in the lymphoreticular system in vCTD cases but not in other varieties of human TSEs, the blood of vCTD-infected individuals may contain priors. The amount of vCTD prions that might be contained in blood and the amount that constitutes an IU are important public health questions. The committee concluded that there is a small but unknown level of risk of acquiring vCTD from blood products; therefore, more research to clarify the nature of that risk should be conducted. Recommendation 5.1: Fund research (1 ) to determine the amount of sporadic Creutzfel~t-lakob disease (sCID) prions and variant Creutzfel~t-Jakob disease (vCJD) prions in human blood and (2) to
OCR for page 14
4 ADVANCING PRION SCIENCE estimate the amount of PrPSc corresponding to one infectious unit of sCID and vCID prions in human blood. The technical feat of developing a prototype test to detect low, and possibly changing, levels of prions in blood is an enormous challenge. But that is only one of the steps necessary to field a new commercial blood- screening test. To avoid false-positive test results, multiple testing schemes should be developed so that results can be confirmed or refuted. Stable, standard, and reliable testing reagents should be developed. Biotechnology companies must be properly structured to successfully mass-produce a novel test. Users will need to develop ethically sound counseling and notification policies for those tested, especially to deal with positive tests. Developers will need to demonstrate and document the test's performance rigorously enough to achieve FDA approval. Finally, a market for the product must exist, or be created, to attract commercial investment and manufacturing. These tasks are achievable with great resolve. SURVEILLANCE FOR TSEs IN THE UNITED STATES Surveillance for TSEs in humans and animals can permit the detection of potential outbreaks of known or new TSEs and the monitoring of those TSEs known to occur in the United States: CWD and scrapie in animals, and sCJD, iatrogenic CJD (iCJD), familial CJD, familial fatal insomnia, sporadic fatal insomnia, and Gerstmann-Straussler-Scheinker disease in humans. Surveillance for TSEs in Humans The Centers for Disease Control and Prevention (CDC) monitors the U.S. population for human TSEs. It also conducts surveillance specifically for vC}D (Belay et al., 2003), even though there has never been a reported case of BSE in the United States. Human TSEs are reportable in 12 states. Identification and Autopsy of TSE Cases The diagnosis of TSE in humans almost always requires a neuropatho- logical examination. These examinations are conducted for the U.S. popu- lation by the National Prion Disease Pathology Surveillance Center (NPDPSC). Yet at least half of the estimated total number of deaths caused by TSE in the United States are not autopsied and confirmed by laboratory examination (Gambetti, 2002; Holman et al., 1996~. The committee con- cluded that the large percentage of undiagnosed TSE cases represents a major obstacle to thorough U.S. surveillance for human TSEs. Physicians
OCR for page 15
SUMMAR Y 15 and public health officials need to identify more suspected TSE cases, and more of those cases should be autopsied and sent to NPDPSC for neuro- pathological examination. As noted earlier, the knowledge that BSE can cross the species barrier into humans has generated concern that CWD, which is epidemic in U.S. deer and elk, could potentially infect humans as well. If so, the human form of CWD could manifest itself clinically in a form quite unlike that of the known human TSEs. Therefore, the committee believes it would be prudent for CDC to conduct TSE surveillance on all atypical cases of neurodegenerative disease. Recommendation 6.1: Provide funds to promote an increase in the proportion of cases of human neurodegenerative disease, especially suspected cases of transmissible spongiform encephalopathy, that are recognized and autopsied. Epidemiological Research on Human TSEs Improving U.S. surveillance for human TSEs will also depend on infor- mation gleaned from epidemiological studies that help define the target population and hone survey instruments. Recommendation 6.2: Provide funds to increase the number and diversity of epidemiological studies on human transmissible spongiform encephalopathies (TSEs) in the United States. In par- ticular, support research to identify potential cases of variant Creutzfel~t-lakob disease and new human TSEs possibly caused by the agent of chronic wasting disease. Surveillance for TSEs in Animals Chronic Wasting Disease Although CWD has existed in deer and elk in Colorado and Wyoming since at least the 1960s (Miller et al., 2000; Williams and Young, 1980), the disease has apparently4 spread to captive and free-ranging herds in 10 other states and two Canadian provinces since 1996 (Fischer and Nettles, 2003; Williams and Miller, 20021. Nationwide surveillance for CWD is improv- ing thanks to increased awareness of the disease and the availability of more resources, including a network of USDA laboratories that conduct neuropathological examinations on possible and probable CWD cases. 4It is also possible that increased awareness of CWD has brought preexisting cases to light for the first time.
OCR for page 22
22 ADVANCING PRION SCIENCE proteomics, building a stronger foundation for future endeavors to de- velop TSE therapeutics. The committee believes the most promising candidates for near-term therapeutics are synthetic products such as peptides, antibodies, or anti- body fragments (scFvs) that bind to specific epitopes on prpC or PrPSc and disrupt further PrP conversion (Enari et al., 2001; Heppner et al., 2001; Peretz et al., 2001; Sigurdsson et al., 2003; White et al., 20031. To realize the promise of these synthetic products, researchers will need to uncover and target specific structural sites on PrPC, PrPSc, or intermediate molecules involved in PrP conversion. Recommendation 7.7: Fund research to develop new therapeutic agents, including antibodies, that either block the conversion of prpc to PrPSc or disrupt the molecular mechanisms of pathogenesis of transmissible spongiform encephalopathies after this conversion has taken place. The most promising approach appears to be ra- tional drug design, which begins with knowledge of the tertiary structure of the protein or molecule that the therapeutic agent will target. The clues that lead to success in diagnostics will help uncover new thera- peutic agents. Likewise, having preclinical diagnostic tests for TSEs will make early treatment and a better prognosis possible. RESEARCH INFRASTRUCTURE The committee determined that prion science would advance more rap- idly in the United States if more investigators worked in this small research community and if more funds were consistently available. The U.S. infra- structure for TSE research, though of high quality, is small compared with its European counterpart. At present fewer than 20 principal investigators conduct prion research funded by the National Institutes of Health (NIH), the largest sponsor of TSE research in the United States. In fiscal year 2002, NIH spent $27.2 million of its total budget of $23.2 billion on TSE research (personal communication, R. Zalusky, National Institute of Neurological Disorders and Stroke, May 27, 20031. Furthermore, 75 percent of the NIH funds awarded for TSE research go to only two laboratories (personal communication, R. T. Johnson, special consultant to NIH on TSEs, 20021. Investigators and Facilities It has been difficult to attract new investigators to prion research for several reasons. First is the lack of available laboratory space and the high start-up costs associated with setting up a TSE research laboratory. Such
OCR for page 23
SUMMAR Y 23 laboratories have special containment requirements and rely on costly labo- ratory animals and dedicated equipment that cannot be shared with other researchers because of concerns about cross-contamination. Second, confu- sion exists within the TSE research community about biosafety-level (BSL) requirements. Formal standards should replace the presently informal and inconsistent guidance in this area. Third, it often takes years to reach ex- perimental end points because prion diseases have relatively long incuba- tion periods. This makes it difficult to attract doctoral and postdoctoral fellows, whose academic programs last for a relatively short time. Recommendation 8.1: Provide funds to attract and train more in- vestigators in prion disease research. In addition, for investigators conducting prion bioassay research, provide grants for 5- to 7-year periods. Recommendation 8.2: Provide funds to boost the capacity of the U.S. infrastructure for research on transmissible spongiform en- cephalopathies by expanding or upgrading existing laboratories, animal facilities, and containment laboratories (biological safety levels 2 and 3), and by building new ones. Recommendation 8.3: Provide funds to develop scientifically based biological safety level standards for laboratories conducting re- search that involves infectious agents known to cause transmissible spongiform encephalopathies. If embraced by the community of organizations that fund TSE research, nationwide BSL standards could serve as a common, consistent framework for regulations governing laboratory biosafety for the full spectrum of TSE research. Reagents Because prion biology is a relatively new science, many of the reagents and other materials used by investigators are not commercially available, so each laboratory has needed to produce its own. Consequently, standardiza- tion of these reagents and materials across different laboratories or even within the same laboratory is lacking. As a result, the experimental conclu- sions reported by investigators can be difficult to replicate and easy to chal- lenge. The committee views this as an area that would benefit from atten- tion and funding. Recommendation 8.4: Provide funds to support new or established transmissible spongiform encephalopathy (TSE) repositories that
OCR for page 24
24 ADVANCING PRION SCIENCE contain a collection of reference materials and genetically engi- neered animals (including transgenic mice), as well as reagents use- ful for developing TSE diagnostics and for other TSE research. All registered investigators involved in prion research should have ac- cess to these collections. Recommendation 8.5: Provide funds to support the U.S. Food and Drug Administration's development of panels of reference reagents needed to evaluate the performance characteristics of tests designed to detect the prion protein and TSE infectivity. These panels would be used to confirm the performance characteristics of test kits be- fore they are approved for public use, as well as to perform quality control on test kit lots before their release to the market. International Collaboration An additional strategy to improve TSE research capacity is to find more opportunities for U.S. researchers to work with investigators in Europe and elsewhere. The committee believes that exploiting opportunities for U.S. investigators to conduct TSE research on site in a European laboratory or to work in a collaborative fashion with a European investigator on a joint research project is not only feasible but also highly desirable. Recommendation 8.6: Provide funds to enable U.S.-based investi- gators of transmissible spongiform encephalopathies (TSEs) to col- laborate or train with TSE investigators internationally and to use TSE research facilities abroad. Exploiting such opportunities will expand the range of TSE research that U.S. scientists can conduct. THE RISK OF TSEs TO THE U.S. MILITARY The committee deliberated upon the risk of prion infection to members of the U.S. military and their families who are or have been deployed to Europe. Discussions focused mainly on the possibilities for consumption of beef products or transfusion of blood products contaminated by priors. The food and blood supplies of deployed U.S. troops are closely controlled and generally originate at U.S. sources. However, some beef products sold in U.S. military commissaries and post exchanges (commonly known as PXs) in Europe were procured from suppliers in the United Kingdom and continental Europe that later reported cases of BSE among their livestock. In exceptional circumstances, some therapeutic blood is also obtained from a host nation's medical facilities.
OCR for page 25
SUMMAR Y 25 The committee determined that the U.S. military is at an increased risk for acquiring vCTD as a result of its deployment to Europe. However, that risk was judged to be small and certainly less than that of the local popula- tion in the United Kingdom and other European countries reporting BSE. Recommendation 9.1: Use existing passive surveillance systems to monitor the incidence of Creutzfel~t-lakob disease and variant Creutzfel~t-lakob disease among individuals receiving medical care from the health systems of the U.S. Department of Defense and the Department of Veterans Affairs. CONCLUSION This final report of the IOM Committee on Transmissible Spongiform Encephalopathies: Assessment of Relevant Science provides an unprec- edented overview of the ways in which TSEs impact human and animal health from donated blood to deer hunting. The committee's recommen- dations are intended to provide guidance to the NPRP on the most pressing TSE research needs. This report should also serve as a useful reference for those interested in TSEs worldwide. Educated laypeople, physicians, scien- tists, and TSE experts should all find herein relevant and readable informa- tion about deadly diseases that appear to be caused by a new and mysteri- ous biological mechanism.
OCR for page 26
26 ADVANCING PRION SCIENCE TABLE S-1 Committee Recommendations by Functional Area and Priority for the National Prion Research Program Recommendation Priority (1 = highest) Basic Research 3.1 Fund basic research to elucidate: (1) the structural features of prions (2) the molecular mechanisms of prion replication (3) the mechanisms of pathogenesis of transmissible spongiform encephalopathies (4) the physiological function of prpC Improving Diagnostics Fund research to: 1 4.1 Develop new assays most likely to achieve quantum leaps in the quality of prion detection tools, rather than incremental improve- ments to existing tests. Any efforts to improve existing tests should aim to increase their sensitivities by several orders of magnitude (at least 103). The optimal test should detect less than 1 infectious unit (IU) of PrPSc per unit of ultimate product used (e.g., 1 liter of blood or 100 grams of beef). 1 4.2 Improve in vitro techniques that amplify small amounts of PrPSc to enhance the sensitivities of diagnostic tests. 4.3 Develop novel methods and reagents that detect or bind to priors, 1 including new antibodies, peptides, nucleic acids, synthetic derivatives, and chimeric molecules. This research could lead not only to better diagnostics, but also to better therapeutic and prophylactic strategies. 4.4 Identify surrogate markers or signatures for the detection of prions or 3 . prlon c .lseases. 4.5 Improve techniques for propagating prions in cultured cells and develop new in vitro cell systems as a means to assay and study priors. 4.6 Develop functional imaging for the presence of PrPSc in brain tissue, leading to an early diagnostic test similar to the imaging diagnostics being developed for Alzheimer's disease. Testing Blood for Evidence of TSEs 3 5.1 Fund research (1) to determine the amount of sporadic Creutzleldt- 1 Jakob disease (sCJD) prions and variant Creutzleldt-Jakob disease (vCJD) prions in human blood and (2) to estimate the amount of PrPSc corresponding to one infectious unit of sCJD and vCJD prions in human blood.
OCR for page 27
SUMMAR Y TABLE S-1 Continued 27 Recommendation Priority (1 = highest) U.S. Surveillance for TSEs Provide funds to: 6.1 Promote an increase in the proportion of cases of human neurodegenerative disease, especially suspected cases of transmissible spongiform encephalopathy, that are recognized and autopsied. 6.2 Increase the number and diversity of epidemiological studies on human transmissible spongiform encephalopathies (TSEs) in the United States. In particular, support research to identify potential cases of variant Creutzieldt-Jakob disease and new human TSEs possibly caused by the agent of chronic wasting disease. 2 2 6.3 Support the development of a nationwide surveillance system for 2 chronic wasting disease in the United States. 6.4 Expand research on the natural history, prevalence, distribution, exposure and transmission characteristics, host susceptibility, and host range of transmissible spongiform encephalopathies, especially chronic wasting disease. Assessment of Strategies to Prevent and Treat TSEs 7.1 Fund research to improve rapid, accurate, and affordable screening assays for central nervous system (CNS) tissue such that the assays can specifically identify CNS material from cattle in processed meat products. 1 7.2 Fund risk assessments that characterize the exposure of hunters, 3 cervid processing establishments, and consumers to the infectious agent of chronic wasting disease. Fund research to: 7.3 Develop novel methods for removing prions from or inactivating prions in blood products and tissues in vitro, using physical, chemical, or immune mechanisms alone or in combination. 7.4 Develop standard assays for the detection of PrPSc or TSE infectivity on the surfaces of reusable medical instruments and materials, as well as research to develop better methods to disinfect such instruments and materials. 2 2 7.5 Develop standard test methods for detecting prion contamination in 3 environmental samples. Continued
OCR for page 28
28 TABLE S-1 Continued ADVANCING PRION SCIENCE Recommendation Priority (1 = highest) 7.6 Identify safe, cost-effective disposal mechanisms for animals and rendered waste infected with agents of transmissible spongiform encephalopathies. This research would best be conducted with a multidisciplinary approach involving experts in such fields as prion biology, biochemistry, environmental engineering, and commercial disposal technology. 7.7 Develop new therapeutic agents, including antibodies, that either block the conversion of prpC to PrPSc or disrupt the molecular mechanisms of pathogenesis of transmissible spongiform encephalopa- thies after this conversion has taken place. The most promising approach appears to be rational drug design, which begins with knowledge of the tertiary structure of the protein or molecule that the therapeutic agent will target. Prion Research Infrastructure Provide funds to: 8.1 Attract and train more investigators in prion disease research. In addition, for investigators conducting prion bioassay research, provide grants for 5- to 7-year periods. 1 8.2 Boost the capacity of the U.S. infrastructure for research on transmis- sible spongiform encephalopathies by expanding or upgrading existing laboratories, animal facilities, and containment laboratories (biologi- cal safety levels 2 and 3), and by building new ones. Provide funds to: 8.3 Develop scientifically based biological safety level standards for laboratories conducting research that involves infectious agents known to cause transmissible spongiform encephalopathies. 8.4 Support new or established transmissible spongiform encephalopathy (TSE) repositories that contain a collection of reference materials and genetically engineered animals (including transgenic mice), as well as reagents useful for developing TSE diagnostics and for other TSE research. All registered investigators involved in prion research should have access to these collections. 8.5 Support the U.S. Food and Drug Administration's development of panels of reference reagents needed to evaluate the performance characteristics of tests designed to detect the prion protein and TSE 2 3
OCR for page 29
SUMMAR Y TABLE S-1 Continued 29 Recommendation Priority (1 = highest) infectivity. These panels would be used to confirm the performance characteristics of test kits before they are approved for public use, as well as to perform quality control on test kit lots before their release to the market. 8.6 Enable U.S.-based investigators of transmissible spongiform encepha- lopathies (TSEs) to collaborate or train with TSE investigators internationally and to use TSE research facilities abroad. Exploiting such opportunities will expand the range of TSE research that U.S. . . scientists can cone uct. Risks to the U.S. Military 9.1 Use existing passive surveillance systems to monitor the incidence of Creutzieldt-Jakob disease and variant Creutzieldt-Jakob disease among individuals receiving medical care from the health systems of the U.S. Department of Defense and the Department of Veterans Affairs. 3 REFERENCES APHIS (Animal and Plant Health Inspection Service). 2003. BSE Surveillance: Yearly Totals May 1990-FY 2003. [Online]. Available: http://www.aphis.usda.gov/lpa/issues/bse/sur- veillance/figure3.html [accessed June 18, 2003]. Belay ED, Maddox RA, Gambetti P. Schonberger LB. 2003. Monitoring the occurrence of emerging forms of Creutzieldt-Jakob disease in the United States. Neurology 60(2):176- 181. Brown P. 2001. Creutzieldt-Jakob disease: blood infectivity and screening tests. Seminars in Hematology 38(4 Supplement 9):2-6. Brown P. 2002. Drug therapy in human and experimental transmissible spongiform encepha- lopathy. Neurology 58(12):1720-1725. Brown P. Cervenakova L, McShane LM, Barber P. Rubenstein R. Drohan WN. 1999. Further studies of blood infectivity in an experimental model of transmissible spongiform en- cephalopathy, with an explanation of why blood components do not transmit Creutzieldt- Jakob disease in humans. Transfusion 39(11-12):1169-1178. Brown P. Gibbs CJ Jr, Rodgers-Johnson P. Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. 1994. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Annals of Neurology 35(5):513-529. Brown P. Preece M, Brandel JP, Sato T. McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenakova L, Fradkin J. Schonberger LB, Collins SJ. 2000a. Iatrogenic Creutzieldt-Jakob disease at the millennium. Neurology 55(8):1075- 1081.
OCR for page 30
30 ADVANCING PRION SCIENCE Brown P. Rau EH, Johnson BK, Bacote AK, Gibbs CJ Jr, Gajdusek DC.2000b. New studies on the heat resistance of hamster-adapted scrapie agent: threshold survival after ashing at 600 degrees C suggests an inorganic template of replication. Proceedings of the National Academy of Sciences of the United States of America 97(7):3418-3421. Caughey B. 2001. Prion protein interconversions. Philosophical Transactions of the Royal Society of London. Series B.: Biological Sciences 356(1406):197-200; Discussion 200- 202. CDC (Centers for Disease Control and Prevention). 1999. Ten great public health achieve- ments in the 20th century. Morbidity and Mortality Weekly Report 48(12):241-244. CWD Task Force. 2002. Plan for Assisting States, Federal Agencies, and Tribes in Managing Chronic Wasting Disease in Wild and Captive Cervids. [Online]. Available: http:// aphisweb.aphis.usda.gov/lpa/issues/cwd/cwd62602.html [accessed March 24, 2003]. Enari M, Flechsig E, Weissmann C. 2001. Scrapie prion protein accumulation by scrapie- infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Pro- ceedings of the National Academy of Sciences of the United States of America 98(16):9295-9299. Fischer JR, Nettles VF. 2003. National chronic wasting disease surveillance in free-ranging cervids: accomplishments and needs. Proceedings of the 106th Annual Meeting of the United States Animal Health Association. St. Louis, MO: United States Animal Health · . . Association. FSIS (Food Safety and Inspection Service). 2002. FSIS Directive 7160.3: Advanced Meat Re- covery Using Beef Vertebral Raw Materials. [Online]. Available: http://www.fsis.usda. gov/OPPDE/rdad/FSISDirectives/7160.3.htm [accessed July 2003]. FSIS. 2003. USDA Begins Sampling Program for Advanced Meat Recovery Systems. [Online]. Available: http://www.fsis.usda.gov/oa/news/2003/amrsampling.htm [accessed June 9, 2003]. Gambetti P. 2002. TSE Surveillance of Humans in the United States. Presentation to the IOM Committee on Transmissible Spongiform Encephalopathies: Assessment of Relevant Sci- ence, Meeting 1. Washington, DC: National Academy Press. GAO (U.S. General Accounting Office). 2002. Mad Cow Disease: Improvements in the Ani- mal Feed Ban and Other Regulatory Areas Would Strengthen U.S. Prevention Efforts. GAO-02-183. Washington, DC: GAO. Harvard Center for Risk Analysis and Tuskegee University Center for Computational Epide- miology. 2001. Evaluation of the Potential for Bovine Spongiform Encephalopathy in the United States. Harvard School of Public Health and College of Veterinary Medicine, Tuskegee University. Washington, DC: U.S. Department of Agriculture. [Online]. Avail- able: http://www.aphis.usda.gov/lpa/issues/bse/bse-riskassmt.html [accessed July 2003] . Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T. Oesch B. Zinkernagel RM, Kalinke U. Aguzzi A. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti- prion protein antibodies. Science 294(5540):178-182. Holman RC, Khan AS, Belay ED, Schonberger LB. 1996. Creutzieldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerging Infectious Diseases 2(4):333-337. Holscher C, Delius H. Burkle A. 1998. Overexpression of nonconvertible PrPc deltall4-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild- type PrP(Sc) accumulation. Journal of Virology 72(2):1153-1159. Hoots WK, Abrams C, Tankersley D. 2001. The Food and Drug Administration's perspective on plasma safety. Transfusion Medicine Reviews 15(2 Supplement 1):20-26. Huillard d'Aignaux JN, Cousens SN, Maccario J. Costagliola D, Alpers MP, Smith PG, Alperovitch A. 2002. The incubation period of kuru. Epidemiology 13(4):402-408.
OCR for page 31
SUMMAR Y 31 Hunter N. Foster J. Chong A, McCutcheon S. Parnham D, Eaton S. MacKenzie C, Houston F. 2002. Transmission of prion diseases by blood transfusion. Journal of General Virology 83(Pt 11):2897-2905. Means WJ. 2003. Processing Deer and Elk Meat in the United States and Intersections with Commercial Beef Processing. Presentation to the IOM Committee on Transmissible Spongiform Encephalopathies, Assessment of Relevant Science, Meeting 5. Washington, DC. Meier P. Genoud N. Prinz M, Maissen M, Rulicke T. Zurbriggen A, Raeber AJ, Aguzzi A. 2003. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 113(1):49-60. Miekka SI, Forng RY, Rohwer RG, MacAuley C, Stafford RE, Flack SL, MacPhee M, Kent RS, Drohan WN. 2003. Inactivation of viral and prion pathogens by gamma-irradiation under conditions that maintain the integrity of human albumin. Vox Sanguinis 84(1):36- 44. Miller MW, Williams ES, McCarty CW, Spraker TR, Kreeger TJ, Larsen CT, Thorne ET. 2000. Epizootiology of chronic wasting disease in free-ranging cervids in Colorado and Wyoming. Journal of VDildlife Diseases 36(4):676-690. National Creutzieldt-Jakob Disease Surveillance Unit. 2003. CJD Statistics. [Online]. Avail- able: http://www.cjd.ed.ac.uk/figures.htm [accessed September 4, 2003]. Peretz D, Williamson RA, Kaneko K, Vergara J. Leclerc E, Schmitt-Ulms G. Mehlhorn IR, Legname G. Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB. 2001. Anti- bodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412(6848):739-743. Perrier V, Kaneko K, Safar J. Vergara J. Tremblay P. DeArmond SJ, Cohen FE, Prusiner SB, Wallace AC.2002. Dominant-negative inhibition of prion replication in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 99(20):13079-13084. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA.2002a. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572-577. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani AM, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. 2002b. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 94(20):1576-1578. PL 107-9 Federal Inter-agency Working Group. 2003. Animal Disease Risk Assessment, Pre- vention, and Control Act of 2001 (PL 107-9): Final Report. [Online]. Available: http:// www.aphis.usda.gov/lpa/pubs/pubs/PL107-9_1-03.pdf [accessed April 21, 2003]. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216(4542):136-144. Saborio GP, Permanne B. Soto C. 2001. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411(6839):810-813. Scientific Steering Committee. 2003. Opinion on the Use of Burial for Dealing with Animal Carcasses and Other Animal Materials That Might Contain BSE/TSE. Brussels: Health and Consumer Protection Directorate-General, European Commission. Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R. Carp R. Meeker HC, Frangione B. Wisniewski T. 2002. Immunization delays the onset of prion disease in mice. American Journal of Pathology 161(1):13-17. Sigurdsson EM, Sy MS, Li R. Scholtzova H. Kascsak RJ, Kascsak R. Carp R. Meeker HC, Frangione B. Wisniewski T.2003. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neuroscience Letters 336(3):185-187. Tateishi J. Kitamoto T. Mohri S. Satoh S. Sato T. Shepherd A, Macnaughton MR. 2001. Scrapie removal using Planova virus removal filters. Biologicals 29(1):17-25.
OCR for page 32
32 ADVANCING PRION SCIENCE Taylor DM.2000. Inactivation of transmissible degenerative encephalopathy agents: a review. Veterinary Journal 159(1):10-17. Trejo SR, Hotta JA, Lebing W. Stenland C, Storms RE, Lee DC, Li H. Petteway S. Remington KM. 2003. Evaluation of virus and prion reduction in a new intravenous immunoglobu- lin manufacturing process. Vox Sanguinis 84(3):176-187. U.S. Senate Committee on Appropriations. 2001. Senate Report 107-109. Department of De- fense Appropriation Bill, 2002 and Supplemental Appropriations, 2002. Title VI. Public Law 107-117, H.R. 3338. Washington, DC: U.S. Congress. White AR, Enever P. Tayebi M, Mushens R. Linehan J. Brandner S. Anstee D, Collinge J. Hawke S. 2003. Monoclonal antibodies inhibit prion replication and delay the develop- ment of prion disease. Nature 422(6927):80-83. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S. Pocchiari M, Hoiman A, Smith PG. 1996. A new variant of Creutzieldt-Jakob disease in the UK. Lancet 347(9006):921-925. Williams ES, Miller MW. 2002. Chronic wasting disease in deer and elk in North America. Revue Scientifique et Technique 21(2):305-316. Williams ES, Young S. 1980. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. Journal of VDildlife Diseases 16(1):89-98.
Representative terms from entire chapter: